{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:37:56Z","timestamp":1788784676591,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ctrv.2025.103068","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:24:24Z","timestamp":1765931064000},"page":"103068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["AMH as a marker for resumption of ovarian function after chemotherapy: an IPD meta-analysis and systematic review"],"prefix":"10.1016","volume":"142","author":[{"given":"Charissa","family":"van Zwol \u2013 Janssens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"van M. Rosmalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop S.E.","family":"Laven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Nasserinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny A.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Ben-Aharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Freour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Irene","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne V.","family":"Louwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ctrv.2025.103068_b0005","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(17)30677-0","article-title":"Cancer incidence and mortality among young adults aged 20\u201339 years worldwide in 2012: a population-based study","volume":"18","author":"Fidler","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103068_b0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/j.seminoncol.2009.03.001","article-title":"Breast cancer before age 40 years","volume":"36","author":"Anders","year":"2009","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103068_b0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1005792830054","article-title":"Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications","volume":"43","author":"Del Mastro","year":"1997","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"10.1016\/j.ctrv.2025.103068_b0020","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","article-title":"Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer","volume":"362","author":"Swain","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103068_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/s12958-015-0134-9","article-title":"Role of anti-m\u00fcllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review","volume":"13","author":"Dumont","year":"2015","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103068_b0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/humupd\/dmac004","article-title":"Anti-Mullerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review","volume":"28","author":"Anderson","year":"2022","journal-title":"Hum Reprod Update"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103068_b0035","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMra000471","article-title":"Production and actions of estrogens","volume":"346","author":"Gruber","year":"2002","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103068_b0040","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0959-8049(02)00810-9","article-title":"The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women","volume":"39","author":"Robertson","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103068_b0045","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","volume":"364","author":"Riley","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2025.103068_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103068_b0055","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/07357900701829777","article-title":"A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer","volume":"26","author":"Anders","year":"2008","journal-title":"Cancer Invest"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103068_b0060","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2010-2582","article-title":"Pretreatment serum anti-m\u00fcllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer","volume":"96","author":"Anderson","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.103068_b0065","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2017.10.001","article-title":"The utility of anti-M\u00fcllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer","volume":"87","author":"Anderson","year":"2017","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2025.103068_b0070","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1016\/j.ejca.2013.07.014","article-title":"Pretreatment anti-M\u00fcllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer","volume":"49","author":"Anderson","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103068_b0075","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1634\/theoncologist.2015-0044","article-title":"Long-term follow-up of chemotherapy-induced ovarian failure in young breast cancer patients: the role of vascular toxicity","volume":"20","author":"Ben-Aharon","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2025.103068_b0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13048-015-0209-4","article-title":"Age, anti-mullerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide","volume":"8","author":"D'Avila","year":"2015","journal-title":"J Ovarian Res"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103068_b0085","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.ogx.0000547762.32638.19","article-title":"Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy","volume":"73","author":"Decanter","year":"2018","journal-title":"Obstet Gynecol Surv Rev"},{"key":"10.1016\/j.ctrv.2025.103068_b0090","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2017.03.035","article-title":"Prospective evaluation of serum anti-M\u00fcllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer","volume":"79","author":"Dezellus","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103068_b0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2021.04.038","article-title":"Chemotherapy-induced ovarian failure in young women with early breast cancer: prospective analysis of four randomised neoadjuvant\/adjuvant breast cancer trials","volume":"152","author":"Furlanetto","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103068_b0100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.rbmo.2014.07.008","article-title":"Ovarian reserve in breast cancer: Assessment with anti-M\u00fcllerian hormone","volume":"29","author":"Hamy","year":"2014","journal-title":"Reprod BioMed Online"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103068_b0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1634\/theoncologist.2013-0145","article-title":"Prediction of postchemotherapy ovarian function using markers of ovarian reserve","volume":"19","author":"Henry","year":"2014","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103068_b0110","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10549-018-4863-2","article-title":"Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy","volume":"171","author":"Lee","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103068_b0115","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/annonc\/mdx184","article-title":"GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial","volume":"28","author":"Leonard","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103068_b0120","doi-asserted-by":"crossref","first-page":"8171","DOI":"10.2147\/CMAR.S269249","article-title":"Can anti-m\u00fcllerian hormone be a reliable biomarker for assessing ovarian function in women postchemotherapy?","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manage Res"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103068_b0125","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/ijc.33933","article-title":"Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients","volume":"150","author":"Mailliez","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103068_b0130","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.clbc.2018.10.003","article-title":"Impact of chemotherapy-induced menopause in women of childbearing age with non-metastatic breast cancer - preliminary results from the MENOCOR study","volume":"19","author":"Passildas","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103068_b0135","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.fertnstert.2009.02.043","article-title":"Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age","volume":"94","author":"Rosendahl","year":"2010","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103068_b0140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10549-014-2891-0","article-title":"Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103","volume":"144","author":"Ruddy","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2025.103068_b0145","article-title":"Anti-mullerian hormone as a serum biomarker for risk of chemotherapy-induced amenorrhea","author":"Ruddy","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103068_b0150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13048-019-0581-6","article-title":"Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments","volume":"12","author":"Silva","year":"2019","journal-title":"J Ovarian Res"},{"issue":"23","key":"10.1016\/j.ctrv.2025.103068_b0155","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cncr.28942","article-title":"Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients","volume":"120","author":"Su","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.103068_b0160","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.breast.2017.07.007","article-title":"Anti-M\u00fcllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy \u2013 a translational research project of the SUCCESS a study","volume":"35","author":"Trapp","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2025.103068_b0165","doi-asserted-by":"crossref","DOI":"10.1093\/humrep\/deaa349","article-title":"Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China","author":"Wang","year":"2021","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103068_b0170","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/s12885-017-3593-x","article-title":"Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial","volume":"17","author":"Wenners","year":"2017","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103068_b0175","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10549-018-4997-2","article-title":"Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer","volume":"173","author":"Xue","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103068_b0180","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.25037","article-title":"Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy","volume":"116","author":"Yu","year":"2010","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103068_b0185","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.7150\/jca.31859","article-title":"GnRHa for ovarian protection and the association between AMH and ovarian function during adjuvant chemotherapy for breast cancer","volume":"10","author":"Zhong","year":"2019","journal-title":"J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103068_b0190","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.rbmo.2019.06.001","article-title":"Five-year study assessing the clinical utility of anti-M\u00fcllerian hormone measurements in reproductive-age women with cancer","volume":"39","author":"Palinska-Rudzka","year":"2019","journal-title":"Reprod BioMed Article"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103068_b0195","doi-asserted-by":"crossref","first-page":"733","DOI":"10.15537\/smj.2018.7.21897","article-title":"Serum anti-m\u00fcllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer: a follow-up study","volume":"39","author":"Al-Rawi","year":"2018","journal-title":"Saudi Med J"},{"key":"10.1016\/j.ctrv.2025.103068_b0200","article-title":"Predicting chemotherapy-induced menopause using baseline and post-chemotherapy anti-Mullerian hormone levels: results of a pilot study","author":"Martin","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103068_b0205","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.fertnstert.2012.09.039","article-title":"Pretreatment antim\u00fcllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy","volume":"99","author":"Dillon","year":"2013","journal-title":"Fertil Steril"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103068_b0210","doi-asserted-by":"crossref","first-page":"e3714","DOI":"10.1210\/clinem\/dgac370","article-title":"Comparison of 3 different AMH assays with AMH levels and follicle count in women with polycystic ovary syndrome","volume":"107","author":"Moolhuijsen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103068_b0215","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12958-020-00641-9","article-title":"Establishment of a WHO Reference Reagent for anti-Mullerian hormone","volume":"18","author":"Ferguson","year":"2020","journal-title":"Reprod Biol Endocrinol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:03:23Z","timestamp":1767168203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"alternative-id":["S0305737225001902"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103068","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AMH as a marker for resumption of ovarian function after chemotherapy: an IPD meta-analysis and systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103068"}}